Chris Shibutani
Stock Analyst at Goldman Sachs
(3.28)
# 926
Out of 4,832 analysts
99
Total ratings
51.92%
Success rate
1.77%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $29.42 | +239.90% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.27 | +136.22% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $6.77 | +121.57% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $30.62 | +4.51% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $92.09 | +48.78% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $9.28 | +255.60% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $299.68 | +0.77% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $32.29 | +57.94% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $146.36 | +5.90% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $4.34 | -7.73% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $8.04 | +148.76% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $715.56 | +1.04% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $23.92 | +8.70% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $118.78 | +28.81% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $177.44 | -2.50% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.72 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $44.12 | +56.39% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $18.03 | -27.88% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $39.47 | -41.73% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.18 | +4,137.29% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $29.75 | +74.79% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $22.02 | +172.48% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $7.98 | +125.56% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.29 | +1,222.96% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.31 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.28 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.91 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.47 | - | 3 | May 2, 2017 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $29.42
Upside: +239.90%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.27
Upside: +136.22%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $6.77
Upside: +121.57%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $30.62
Upside: +4.51%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $92.09
Upside: +48.78%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $9.28
Upside: +255.60%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $299.68
Upside: +0.77%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $32.29
Upside: +57.94%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $146.36
Upside: +5.90%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $4.34
Upside: -7.73%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $8.04
Upside: +148.76%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $715.56
Upside: +1.04%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $23.92
Upside: +8.70%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $118.78
Upside: +28.81%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $177.44
Upside: -2.50%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.72
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $44.12
Upside: +56.39%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $18.03
Upside: -27.88%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $39.47
Upside: -41.73%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $1.18
Upside: +4,137.29%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $29.75
Upside: +74.79%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $22.02
Upside: +172.48%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $7.98
Upside: +125.56%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $1.29
Upside: +1,222.96%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.31
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.28
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $2.91
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $29.47
Upside: -